Target intelligence / Profile preview

Immunoglobulin G1 (IgG1)

Target: IgG1
Molecular classification: Immunoglobulin, Glycoprotein, Antibody, Member of the Immunoglobulin superfamily (IgSF)

Overview

Immunoglobulin G1 is the most abundant subclass of IgG in human serum, accounting for about 60% of IgG. It is a glycoprotein antibody (~146 kDa) formed by two heavy chains (gamma-1) and two light chains (either kappa or lambda), linked by disulfide bonds. Its structure enables high flexibility due to a long hinge region, allowing effective antigen binding and subsequent activation of immune effector mechanisms. IgG1 efficiently binds Fc gamma receptors and complements component C1q, contributing to potent immune defense through opsonization, complement activation, and antibody-dependent cellular cytotoxicity (ADCC). IgG1 is highly efficient in crossing the placenta, providing passive immunity to the fetus. Therapeutically, the IgG1 backbone is used to engineer monoclonal antibody drugs due to its favorable effector profile, but excessive activation or inappropriate immune targeting can result in adverse effects or autoimmune responses[1][3][4].

Other names: IgG1Human IgG1Gamma-1 immunoglobulin

Mechanism of action

Antigen binding and neutralization via Fab region; Fc-mediated effector functions (ADCC: antibody-dependent cellular cytotoxicity; CDC: complement-dependent cytotoxicity); Immune complex formation and clearance

Biological functions

Antigen recognitionOpsonization of pathogensActivation of the classical complement pathwayBinding to Fc gamma receptors (FcγRs) on immune cellsPlacental transfer (provides fetal immunity)Immune complex formation

Disease associations

Infection (especially bacterial and viral)Allergy (involved in response to allergens)Autoimmune disease (target of autoantibodies)Cancer (used in therapeutic monoclonal antibodies)Inflammation

Safety considerations

Immunogenicity of therapeutic IgG1 monoclonal antibodies can lead to anti-drug antibody formation and hypersensitivity reactionsExcessive activation can contribute to autoimmune pathologyRisk of serum sickness with high-dose administration

Interacting drugs

Rituximab (anti-CD20, IgG1 format)

3 more in the full profile.

Biomarkers

Serum IgG1 levels (quantitative immunoglobulin testing used for diagnosis/monitoring of immunodeficiencies, infectious diseases, and some autoimmune conditions)Subclass deficiency as a marker for susceptibility to infections

Beyond the preview

Go deeper on Immunoglobulin G1 (IgG1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin G1 (IgG1).

Explore the full profile